Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans boosted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 70.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 93,427 shares of the life sciences company's stock after acquiring an additional 38,597 shares during the period. Thrivent Financial for Lutherans owned about 0.12% of Integra LifeSciences worth $2,119,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Intech Investment Management LLC purchased a new stake in shares of Integra LifeSciences in the 3rd quarter valued at about $235,000. Charles Schwab Investment Management Inc. lifted its stake in Integra LifeSciences by 15.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company's stock valued at $17,158,000 after buying an additional 125,620 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Integra LifeSciences in the third quarter valued at approximately $198,000. Quantbot Technologies LP increased its holdings in shares of Integra LifeSciences by 230.5% in the 3rd quarter. Quantbot Technologies LP now owns 72,351 shares of the life sciences company's stock valued at $1,315,000 after acquiring an additional 50,459 shares during the period. Finally, BNP Paribas Financial Markets raised its position in Integra LifeSciences by 824.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company's stock valued at $2,031,000 after purchasing an additional 99,685 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Stock Performance

NASDAQ:IART traded up $0.17 during midday trading on Wednesday, reaching $21.78. The stock had a trading volume of 343,336 shares, compared to its average volume of 1,044,862. The stock has a market cap of $1.68 billion, a P/E ratio of -241.97, a P/E/G ratio of 0.73 and a beta of 1.23. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $34.80. The firm has a fifty day simple moving average of $23.61 and a two-hundred day simple moving average of $22.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12. The business had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business's quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.89 earnings per share. On average, equities analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Separately, Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.